Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: Successful treatment with bortezomib

European Journal of Haematology

Volumn 92, Issue 1, 2014, Pages 80-82

  van Balen, Tessa ^a   Schreuder, Michiel F ^a   de Jong, Huib ^a   Van de Kar, Nicole C A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADAMTS13 autoantibodies; Bortezomib; Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

BORTEZOMIB; PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HEART AUSCULTATION; HEMOLYTIC ANEMIA; HUMAN; IMMUNOPHENOTYPING; MICROANGIOPATHY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAMTS13 AUTOANTIBODIES; BORTEZOMIB; PLASMA EXCHANGE; RITUXIMAB; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ANTIBODIES, MONOCLONAL; BORONIC ACIDS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; PYRAZINES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84890200058     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12206     Document Type: Article

References (10)

1. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11.
2. George JN. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 2012;87:S88-91.
3. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Löwenberg B, Brand A. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005;130:768-76.
4. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by Bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013;368:90-2.
5. Tun N, Villani G. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis 2012;34:347-59.
6. McDonald V, Liesner R, Grainger J, Gattens M, Machin SJ, Scully M. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMT13 assays. Blood Coagul Fibrinolysis 2010;21:245-50.
7. Beloncle F, Buffet M, Coindre JP, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012;52:2436-44.
8. Puisset F, White-Koning M, Kamar N, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 2013;76:734-40.
9. Park S, Cheoung H, Shin J. Antibody depletion by bortezomib through blocking of antigen presentation. N Engl J Med 2013;368:1364-5.
10. Eckmann CM, De Laaf RT, Van Keulen JM, Van Mourik JA, De Laat B. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007;5:1330-1.